Search

Now showing items 1-2 of 2

Plerixafor for pbsc mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from europe and the usa

Douglas, K W; Parker, A N; Hayden, P J; Rahemtulla, A; D'Addio, A; Lemoli, R M; Rao, K; Maris, M; Pagliuca, A; Uberti, J; Scheid, C; Noppeney, R; Cook, G; Bokhari, S W; Worel, N; Mikala, G; Masszi, T; Taylor, R; Treisman, J (Springer Nature, 2011-02-28)

We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed mobilisation by conventional ...

Elacytarabine has single-agent activity in patients  with advanced acute myeloid leukaemia

O'Brien, Susan; Rizzieri, David A.; Vey, Norbert; Ravandi, Farhad; Krug, Utz O.; Sekeres, Mikkael A.; Dennis, Mike; Venditti, Adriano; Berry, Donald A.; Jacobsen, Tove Flem; Staudacher, Karin; Bergeland, Trygve; Giles, Francis J. (Wiley-Blackwell, 2012-06-15)

Elacytarabine is a novel cytotoxic nucleoside analogue, independent of nucleoside transporters (e.g. human Equilibrative Nucleoside Transporter 1 [hENT1]) for cell uptake, and mechanisms of action similar to those of ...